Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma

By sjmartinez • November 6, 2022

Gong J, Thomassian S, Kim S, Gresham G, Moshayedi N, Ye JY, Yang JC, Jacobs JP, Lo S, Nissen N, Gaddam S, Tighiouart M, Osipov A, Hendifar A. Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma. Sci Rep. 2022 Nov 4;12(1):18731. doi: 10.1038/s41598-022-23619-6. Erratum for: Sci Rep. 2022 Sep 2;12(1):15013. PMID: 36333397; PMCID: PMC9636406.

Tags: General Internal Medicine, Publications

Identifying Household Diabetes Risk for Family Diabetes Prevention Using Electronic Health Records

Thomas TW, Finertie H, Silverberg A, Yassin M, Patino JE, Rosas LG, Tester J, Rodriguez LA, Duru OK, Schmittdiel JA. Identifying Household Diabetes Risk for[...]

The Promise and Limits of Hybrid Ambient Documentation

Linares M, Mafi JN. The Promise and Limits of Hybrid Ambient Documentation. J Gen Intern Med. 2026 Jan 13. doi: 10.1007/s11606-026-10194-z. Epub ahead of print.[...]

Associations Between Stigma, Discrimination, and HIV Continuum of Care Outcomes Among Criminal Legal-Involved Youth and Young Adults with HIV

Brewer RA, Almirol E, Malagon M, Webb J, Payne D, Seiden DS, McAvoy-Banerjea J, Hernandez DA, Wang L, Mungo L, Schneider JA, Zawitz C, Beltzer[...]